What is Amneal Pharmaceuticals, Inc.'s earnings per share (EPS)?

Amneal Pharmaceuticals, Inc. (AMRX) reported diluted earnings per share of $0.22 for fiscal year 2025. This represents a 157.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Amneal Pharmaceuticals, Inc. (AMRX) Financials

AMRX

Trailing 12 months to June 30, 2026

Revenue $3.1B +9.3% YoY

Net Income $157.4M +4562.6% YoY

EPS (Diluted) $0.49 +4800.0% YoY

Free Cash Flow $127.8M -54.8% YoY

Market Cap $7.1B as of Oct 6, 2026

Price / Sales 2.3x on $3.1B revenue, trailing 12 months to June 30, 2026

Price / Earnings 44.9x on $157.4M net income, trailing 12 months to June 30, 2026

Price / Book 214x on $33.0M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AMRX SEC filings page.

Amneal Pharmaceuticals, Inc. (AMRX) reported $3.1B in revenue over the twelve months to Jun 30, 2026, up 9.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AMRX FY2025 2026-10-04

Amneal's 2025 recovery came from stronger operating efficiency and cash generation, but negative equity and heavy debt remain structural constraints.

Between FY2024 and FY2025, operating margin expanded from 8.9% to 13.1%, showing that more of each sales dollar reached operations. Net margin crossed back into positive territory, yet FY2025 interest expense of $241M remained substantial against $394M of operating income, so financing costs still absorb much of the operating improvement.

Operating cash flow of $340M converted to free cash flow of $270M in FY2025, meaning reinvestment consumed a minority of internally generated cash. That cash conversion pattern indicates the improved operating result was accompanied by cash rather than being purely accounting-based.

Liabilities exceeded assets in FY2025, leaving negative equity of $70.8M; that is a long-term solvency condition distinct from near-term liquidity. The current ratio improved from 1.4x in FY2024 to 2.2x in FY2025, indicating better short-term coverage even while the broader capital structure remains strained.

Financial Health Signals

Financial Health Score 56/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Amneal Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Amneal Pharmaceuticals, Inc. has an operating margin of 13.1%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 60/100, indicating healthy but not exceptional operating efficiency. This is up from 8.9% the prior year.

Growth

Amneal Pharmaceuticals, Inc.'s revenue grew 8.0% year-over-year to $3.0B, a solid pace of expansion. This earns a growth score of 70/100.

Leverage

Liquidity

Amneal Pharmaceuticals, Inc.'s current ratio of 2.17 indicates adequate short-term liquidity, earning a score of 63/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Amneal Pharmaceuticals, Inc. has a free cash flow margin of 8.9%, earning a moderate score of 64/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Altman Z-Score Grey Zone

2.44

Amneal Pharmaceuticals, Inc. scores 2.44, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Amneal Pharmaceuticals, Inc. passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

4.72x

For every $1 of reported earnings, Amneal Pharmaceuticals, Inc. generates $4.72 in operating cash flow ($340.0M OCF vs $72.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

1.63x

Amneal Pharmaceuticals, Inc. earns $1.63 in operating income for every $1 of interest expense ($394.1M vs $241.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$796.2M

YoY+9.9%

QoQ+10.2%

5Y CAGR+8.3%

Amneal Pharmaceuticals, Inc. generated $796.2M in revenue in Q2 2026. This represents an increase of 9.9% from the same quarter a year earlier. Against the prior quarter it is up 10.2%.

Net Income

$57.7M

YoY+157.2%

QoQ-7.4%

5Y CAGR+14.0%

Amneal Pharmaceuticals, Inc. reported $57.7M in net income in Q2 2026. This represents an increase of 157.2% from the same quarter a year earlier. Against the prior quarter it is down 7.4%.

EPS (Diluted)

$0.18

YoY+157.1%

QoQ-5.3%

5Y CAGR+12.5%

Amneal Pharmaceuticals, Inc. earned $0.18 per diluted share (EPS) in Q2 2026. This represents an increase of 157.1% from the same quarter a year earlier. Against the prior quarter it is down 5.3%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$51.9M

YoY-185.2%

QoQ-48.8%

Amneal Pharmaceuticals, Inc. recorded an outflow of $51.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 185.2% from the same quarter a year earlier. Against the prior quarter it is down 48.8%.

Cash & Debt

$127.6M

YoY+78.4%

QoQ-35.4%

5Y CAGR-14.4%

Amneal Pharmaceuticals, Inc. held $127.6M in cash against $2.6B in long-term debt as of Q2 2026.

Shares Outstanding

319M

YoY+1.7%

QoQ+0.1%

Amneal Pharmaceuticals, Inc. had 319M shares outstanding in Q2 2026. This represents an increase of 1.7% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

42.0%

YoY+2.5pp

QoQ-2.3pp

5Y change+2.3pp

Amneal Pharmaceuticals, Inc.'s gross margin was 42.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.3 percentage points.

Operating Margin

16.3%

YoY+0.9pp

QoQ-3.3pp

5Y change+3.8pp

Amneal Pharmaceuticals, Inc.'s operating margin was 16.3% in Q2 2026, reflecting core business profitability. This is up 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.3 percentage points.

Net Margin

7.2%

YoY+4.2pp

QoQ-1.4pp

5Y change+1.6pp

Amneal Pharmaceuticals, Inc.'s net profit margin was 7.2% in Q2 2026, showing the share of revenue converted to profit. This is up 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.4 percentage points.

Return on Equity

174.6%

Amneal Pharmaceuticals, Inc.'s ROE was 174.6% in Q2 2026, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$39.0M

YoY-18.7%

QoQ+1.7%

5Y CAGR-5.9%

Amneal Pharmaceuticals, Inc. invested $39.0M in research and development in Q2 2026. This represents a decrease of 18.7% from the same quarter a year earlier. Against the prior quarter it is up 1.7%.

Capital Expenditures

$30.7M

YoY+34.5%

QoQ+275.5%

5Y CAGR+31.5%

Amneal Pharmaceuticals, Inc. invested $30.7M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 34.5% from the same quarter a year earlier. Against the prior quarter it is up 275.5%.

Share Buybacks

Not reported for Q2 2026.

AMRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMRX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Revenue	$3.1B	$3.0B+8.0%	$2.8B+16.7%	$2.4B+8.2%	$2.2B+5.7%	$2.1B+5.1%	$2.0B+22.5%	$1.6B-2.2%	$1.7B+60.9%	$1.0B+1.5%	$1.0B
Cost of Revenue	$1.9B	$1.9B+7.4%	$1.8B+12.7%	$1.6B+10.2%	$1.4B+7.8%	$1.3B-0.4%	$1.3B+15.9%	$1.1B+22.2%	$938.8M+85.0%	$507.5M+20.6%	$420.8M
Gross Profit	$1.2B	$1.1B+9.1%	$1.0B+24.4%	$820.6M+4.6%	$784.7M+2.0%	$769.0M+22.4%	$628.4M+78.0%	$353.0M-50.7%	$716.4M+36.2%	$526.2M-11.9%	$597.5M
R&D Expenses	$175.6M	$186.2M-2.4%	$190.7M+16.3%	$163.9M-16.2%	$195.7M-3.1%	$201.8M+12.2%	$179.9M-4.3%	$188.0M-3.2%	$194.2M+13.3%	$171.4M-4.2%	$179.0M
SG&A Expenses	$571.9M	$526.8M+10.6%	$476.4M+10.9%	$429.7M+7.5%	$399.7M+9.4%	$365.5M+11.9%	$326.7M+12.8%	$289.6M+27.1%	$227.8M+108.9%	$109.0M-8.2%	$118.8M
Operating Income	$453.9M	$394.1M+58.1%	$249.3M+22.0%	$204.4M+315.3%	-$94.9M-162.2%	$152.7M+67.5%	$91.2M+136.7%	-$248.7M-1164.1%	-$19.7M-108.0%	$245.1M-14.0%	$284.9M
EBITDA	N/A	$622.3M+27.0%	$490.1M+11.7%	$438.7M+192.3%	$150.1M-61.6%	$390.8M+18.1%	$331.0M+971.6%	-$38.0M-120.1%	$188.7M-47.6%	$360.1M+13.3%	$317.9M
Interest Expense	$227.5M	$241.1M-6.8%	$258.6M+22.8%	$210.6M+33.0%	$158.4M+16.2%	$136.3M-6.6%	$146.0M-13.2%	$168.2M+17.2%	$143.6M+102.0%	$71.1M+28.5%	$55.3M
Income Tax	-$14.1M	$11.3M-40.2%	$18.9M+123.2%	$8.5M+26.9%	$6.7M-40.5%	$11.2M+110.7%	-$104.4M-127.2%	$383.3M+27114.2%	-$1.4M-171.0%	$2.0M-63.0%	$5.4M
Net Income	$157.4M	$72.1M+161.6%	-$116.9M-39.2%	-$84.0M+69.0%	-$270.6M-2155.6%	$13.2M-80.6%	$67.8M+111.2%	-$603.6M-2957.0%	-$19.7M	$0	$0
EPS (Basic)	N/A	$0.23+160.5%	-$0.38+20.8%	-$0.48+44.2%	-$0.86-1328.6%	$0.07-88.7%	$0.62+122.6%	-$2.74-1612.5%	-$0.16	N/A	N/A
EPS (Diluted)	$0.49	$0.22+157.9%	-$0.38	-$0.48	-$0.86	$0.07	$0.61	-$2.74	-$0.16	N/A	N/A
Diluted Shares (Avg)	N/A	325M+5.1%	309M	176M	151M	152M	149M	132M	127M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$796.2M+9.9%	$722.5M+3.9%	$814.3M+11.5%	$784.5M+11.7%	$724.5M+3.2%	$695.4M+5.5%	$730.5M+18.4%	$702.5M+13.3%
Cost of Revenue	$461.7M+5.3%	$402.4M-8.4%	$517.1M+10.6%	$510.5M+17.9%	$438.3M-3.0%	$439.5M+4.4%	$467.6M+9.5%	$432.9M+11.7%
Gross Profit	$334.5M+16.9%	$320.1M+25.1%	$297.2M+13.1%	$274.0M+1.6%	$286.3M+14.5%	$255.9M+7.5%	$262.9M+38.5%	$269.6M+15.9%
R&D Expenses	$39.0M-18.7%	$38.4M-4.1%	$34.8M-35.8%	$63.4M+3.7%	$48.0M+33.0%	$40.0M+1.9%	$54.3M+17.7%	$61.1M+47.7%
SG&A Expenses	$148.7M+19.7%	$138.9M+17.4%	$146.5M+13.8%	$137.8M+16.1%	$124.3M+6.7%	$118.3M+5.1%	$128.7M+18.1%	$118.7M+5.0%
Operating Income	$129.8M+16.5%	$141.8M+41.3%	$112.0M+47.8%	$70.3M-20.8%	$111.4M+16.7%	$100.3M+1033.8%	$75.8M+434.0%	$88.8M+17.4%
Interest Expense	$55.0M-15.4%	$53.4M-6.3%	$56.2M-8.8%	$62.8M-4.1%	$65.1M-0.9%	$56.9M-13.3%	$61.7M+3.6%	$65.5M+28.7%
Income Tax	$1.4M-91.5%	$2.2M-83.1%	$5.7M+4.4%	-$23.4M-737.1%	$16.1M+345.0%	$12.9M+109.0%	$5.4M-45.1%	$3.7M+276.6%
Net Income	$57.7M+157.2%	$62.3M+410.5%	$35.1M+212.9%	$2.4M+1618.6%	$22.4M+274.0%	$12.2M+113.3%	-$31.1M+68.5%	-$156K-101.6%
EPS (Basic)	$0.18+157.1%	$0.20+400.0%	$0.11+210.0%	$0.01	$0.07+250.0%	$0.04+113.3%	-$0.10+82.8%	$0.00-100.0%
EPS (Diluted)	$0.18+157.1%	$0.19+375.0%	$0.11+210.0%	$0.01	$0.07+250.0%	$0.04+113.3%	-$0.10	$0.00-100.0%
Diluted Shares (Avg)	328M+1.8%	329M+1.5%	N/A	325M+4.9%	322M+1.1%	324M+5.4%	N/A	310M+93.9%

Not reported in any period shown, so not listed: EBITDA.

AMRX Balance Sheet

AMRX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$3.7B+5.1%	$3.5B+0.8%	$3.5B-8.6%	$3.8B-3.6%	$3.9B-1.7%	$4.0B+9.3%	$3.7B-15.8%	$4.4B+224.4%	$1.3B	N/A
Current Assets	$1.9B+20.4%	$1.6B+15.2%	$1.4B-2.4%	$1.4B-7.1%	$1.5B-2.0%	$1.6B+28.2%	$1.2B-5.9%	$1.3B+66.7%	$771.9M	N/A
Cash & Equivalents	$282.0M+155.1%	$110.6M+20.8%	$91.5M+252.4%	$26.0M-89.5%	$247.8M-27.4%	$341.4M+125.8%	$151.2M-29.1%	$213.4M+187.7%	$74.2M+171.0%	$27.4M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$606.3M-1.0%	$612.5M+5.3%	$581.4M+9.5%	$530.7M+8.4%	$489.4M-0.3%	$490.6M+28.8%	$381.1M-16.7%	$457.2M+61.0%	$284.0M	N/A
Accounts Receivable	N/A	N/A	N/A	$741.8M+12.0%	$662.6M+3.7%	$638.9M+5.7%	$604.4M+25.5%	$481.5M+37.0%	$351.4M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$595.5M-0.3%	$597.4M-0.2%	$598.6M0.0%	$598.9M+1.0%	$593.0M+13.4%	$522.8M+24.6%	$419.5M-1.6%	$426.2M+1511.8%	$26.4M-7.0%	$28.4M
Total Liabilities	$3.7B+3.8%	$3.6B+4.6%	$3.5B-1.4%	$3.5B-2.2%	$3.6B-3.3%	$3.7B+7.8%	$3.4B-10.8%	$3.8B+186.8%	$1.3B	N/A
Current Liabilities	$881.6M-22.0%	$1.1B+33.4%	$846.6M+12.5%	$752.8M+11.2%	$677.2M+0.1%	$676.9M+23.0%	$550.4M-0.6%	$553.9M+86.6%	$296.9M	N/A
Non-Current Liabilities	$2.8B+15.5%	$2.4B-5.8%	$2.6B-9.6%	$2.8B-1.4%	$2.9B-3.2%	$3.0B+7.4%	$2.8B-4.6%	$2.9B	N/A	N/A
Long-Term Debt	$2.6B+18.7%	$2.2B-9.4%	$2.4B-7.9%	$2.6B-3.3%	$2.7B-2.0%	$2.7B+4.8%	$2.6B-0.8%	$2.6B+94.1%	$1.4B	N/A
Total Equity	-$70.8M+35.2%	-$109.3M-652.4%	$19.8M-93.4%	$298.4M-17.2%	$360.3M+18.8%	$303.3M+30.7%	$232.0M-54.0%	$504.8M	$0	N/A
Retained Earnings	-$535.0M+11.9%	-$607.1M-23.8%	-$490.2M-20.7%	-$406.2M-47.1%	-$276.2M+3.7%	-$286.8M+24.1%	-$377.9M-1706.3%	-$20.9M+94.5%	-$382.8M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$3.8B+10.3%	$3.5B+5.2%	$3.7B+5.1%	$3.6B+4.0%	$3.4B-2.5%	$3.4B-2.6%	$3.5B+0.8%	$3.5B-6.1%
Current Assets	$1.9B+22.9%	$1.8B+19.0%	$1.9B+20.4%	$1.8B+21.5%	$1.6B+6.7%	$1.5B+9.4%	$1.6B+15.2%	$1.5B+3.9%
Cash & Equivalents	$127.6M+78.4%	$197.7M+234.0%	$282.0M+155.1%	$201.2M+171.9%	$71.5M+63.5%	$59.2M+27.2%	$110.6M+20.8%	$74.0M-14.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$678.0M+11.3%	$641.6M+6.7%	$606.3M-1.0%	$614.5M+3.0%	$609.0M+5.8%	$601.4M+5.4%	$612.5M+5.3%	$596.4M+3.4%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$593.5M-0.7%	$593.8M-0.6%	$595.5M-0.3%	$595.9M-0.4%	$597.4M-0.2%	$597.5M-0.2%	$597.4M-0.2%	$598.3M-0.1%
Total Liabilities	$3.7B+5.9%	$3.6B+2.5%	$3.7B+3.8%	$3.7B+4.4%	$3.5B-0.9%	$3.5B-0.7%	$3.6B+4.6%	$3.6B+5.9%
Current Liabilities	$883.2M-20.2%	$728.0M-32.3%	$881.6M-22.0%	$862.1M-21.3%	$1.1B-0.6%	$1.1B+28.9%	$1.1B+33.4%	$1.1B+44.0%
Non-Current Liabilities	$2.8B+17.5%	$2.8B+18.0%	$2.8B+15.5%	$2.8B+15.9%	$2.4B-1.6%	$2.3B-11.0%	$2.4B-5.8%	$2.4B-12.3%
Long-Term Debt	$2.6B+19.5%	$2.6B+19.1%	$2.6B+18.7%	$2.6B+18.3%	$2.1B-1.4%	$2.2B-9.4%	$2.2B-9.4%	$2.2B-14.6%
Total Equity	$33.0M+129.5%	-$45.4M+65.5%	-$70.8M+35.2%	-$109.5M-17.2%	-$112.1M-95.1%	-$131.7M-106.6%	-$109.3M-652.4%	-$93.4M-128.2%
Retained Earnings	-$415.1M+27.5%	-$472.7M+20.5%	-$535.0M+11.9%	-$570.1M+1.0%	-$572.5M+0.6%	-$594.9M-2.2%	-$607.1M-23.8%	-$576.0M-47.1%

Not reported in any period shown, so not listed: Accounts Receivable.

AMRX Cash Flow Statement

AMRX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	$200.8M	$340.0M+15.2%	$295.1M-14.6%	$345.6M+430.8%	$65.1M-73.1%	$241.8M-36.2%	$379.0M+22128.8%	$1.7M-99.3%	$250.2M+6.9%	$234.2M+103.5%	$115.1M
Depreciation & Amortization	N/A	$228.2M-5.2%	$240.8M+2.7%	$234.4M-4.3%	$245.0M+2.9%	$238.1M-0.7%	$239.9M+13.8%	$210.7M+1.1%	$208.4M+81.3%	$114.9M+248.2%	$33.0M
Stock-Based Compensation	N/A	$32.0M+15.1%	$27.8M+3.5%	$26.8M-15.8%	$31.8M+12.1%	$28.4M+36.9%	$20.8M-4.3%	$21.7M-87.1%	$167.6M	$0	$0
Capital Expenditures	$72.9M	$70.1M+34.9%	$51.9M+20.1%	$43.2M-6.9%	$46.4M-2.8%	$47.7M-15.4%	$56.4M+19.6%	$47.2M-43.2%	$83.1M-12.3%	$94.8M-22.8%	$122.8M
Free Cash Flow	$127.8M	$269.9M+11.0%	$243.2M-19.6%	$302.4M+1517.5%	$18.7M-90.4%	$194.1M-39.8%	$322.6M+809.3%	-$45.5M-127.2%	$167.1M+19.9%	$139.4M+1911.5%	-$7.7M
Investing Cash Flow	-$212.4M	-$112.3M-78.2%	-$63.0M+9.0%	-$69.2M+60.3%	-$174.3M+10.2%	-$194.2M+38.8%	-$317.5M-1521.8%	-$19.6M+95.1%	-$396.4M-302.2%	-$98.6M+20.9%	-$124.6M
Financing Cash Flow	$69.6M	-$31.5M+85.1%	-$211.8M+0.4%	-$212.6M-99.4%	-$106.6M+22.8%	-$138.1M-204.8%	$131.8M+387.6%	-$45.8M-115.9%	$287.7M+402.8%	-$95.0M-387.4%	-$19.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$183.0M-51.2%	$375.3M+87.1%	$200.6M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$5K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$21.2M-125.3%	-$26.7M-461.0%	$130.3M+10.4%	$118.5M-16.5%	$83.8M+111.4%	$7.4M+268.0%	$118.1M-13.1%	$141.8M+74.2%
Stock-Based Compensation	N/A	$8.8M+21.5%	N/A	N/A	N/A	$7.3M+8.0%	N/A	N/A
Capital Expenditures	$30.7M+34.5%	$8.2M-37.9%	$21.8M+43.7%	$12.3M-27.4%	$22.8M+114.9%	$13.2M+43.1%	$15.2M+53.6%	$16.9M+45.3%
Free Cash Flow	-$51.9M-185.2%	-$34.9M-506.8%	$108.5M+5.5%	$106.2M-15.0%	$61.0M+110.1%	-$5.8M+57.7%	$102.9M-18.3%	$124.8M+79.0%
Investing Cash Flow	-$122.7M-362.4%	-$21.7M-22.0%	-$45.5M-183.0%	-$22.5M-8.5%	-$26.5M-310.6%	-$17.8M+9.9%	-$16.1M+49.3%	-$20.7M-53.7%
Financing Cash Flow	$79.4M+290.4%	-$59.1M-50.8%	-$10.1M+83.5%	$59.4M+164.4%	-$41.7M-18.8%	-$39.2M-69.1%	-$61.2M+39.3%	-$92.3M-6.7%

Not reported in any period shown, so not listed: Depreciation & Amortization, Dividends Paid, Share Buybacks.

AMRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMRX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Gross Margin	36.9%+0.4pp	36.5%+2.2pp	34.3%-1.2pp	35.5%-1.3pp	36.7%+5.2pp	31.5%+9.8pp	21.7%-21.4pp	43.1%-7.8pp	50.9%-7.8pp	58.7%
Operating Margin	13.1%+4.1pp	8.9%+0.4pp	8.5%+12.8pp	-4.3%-11.6pp	7.3%+2.7pp	4.6%+19.9pp	-15.3%-14.1pp	-1.2%-24.9pp	23.7%-4.3pp	28.0%
Net Margin	2.4%+6.6pp	-4.2%-0.7pp	-3.5%+8.7pp	-12.2%-12.9pp	0.6%-2.8pp	3.4%+40.5pp	-37.1%-35.9pp	-1.2%-1.2pp	0.0%0.0pp	0.0%
Return on Equity	N/A	N/A	-424.6%-333.9pp	-90.7%-94.3pp	3.6%-18.7pp	22.4%+282.5pp	-260.2%-256.2pp	-3.9%	N/A	N/A
Return on Assets	2.0%+5.3pp	-3.3%-0.9pp	-2.4%+4.7pp	-7.1%-7.4pp	0.3%-1.4pp	1.7%+18.1pp	-16.5%-16.0pp	-0.4%-0.4pp	0.0%	N/A
Current Ratio	2.17+0.8x	1.41-0.2x	1.63-0.2x	1.88-0.4x	2.240.0x	2.29+0.1x	2.20-0.1x	2.32-0.3x	2.60	N/A
Debt-to-Equity	N/A	N/A	120.62+111.9x	8.69+1.2x	7.44-1.6x	9.02-2.2x	11.25+6.0x	5.21	N/A	N/A
Asset Turnover	0.820.0x	0.80+0.1x	0.69+0.1x	0.58+0.1x	0.530.0x	0.50+0.1x	0.44+0.1x	0.38-0.4x	0.77	N/A
FCF Margin	8.9%+0.2pp	8.7%-3.9pp	12.6%+11.8pp	0.8%-8.4pp	9.3%-6.9pp	16.2%+19.0pp	-2.8%-12.8pp	10.1%-3.4pp	13.5%+14.2pp	-0.8%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	42.0%+2.5pp	44.3%+7.5pp	36.5%+0.5pp	34.9%-3.4pp	39.5%+3.9pp	36.8%+0.7pp	36.0%+5.2pp	38.4%+0.9pp
Operating Margin	16.3%+0.9pp	19.6%+5.2pp	13.8%+3.4pp	9.0%-3.7pp	15.4%+1.8pp	14.4%+16.1pp	10.4%+8.1pp	12.6%+0.4pp
Net Margin	7.2%+4.2pp	8.6%+6.9pp	4.3%+8.6pp	0.3%+0.3pp	3.1%+2.2pp	1.8%+15.7pp	-4.3%+11.7pp	0.0%-1.6pp
Return on Equity	174.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	1.5%+0.9pp	1.8%+1.4pp	0.9%+1.8pp	0.1%+0.1pp	0.7%+0.5pp	0.4%+3.0pp	-0.9%+2.0pp	0.0%-0.3pp
Current Ratio	2.20+0.8x	2.47+1.1x	2.17+0.8x	2.13+0.8x	1.43+0.1x	1.40-0.3x	1.41-0.2x	1.38-0.5x
Debt-to-Equity	77.65	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.210.0x	0.200.0x	0.220.0x	0.220.0x	0.210.0x	0.210.0x	0.210.0x	0.200.0x
FCF Margin	-6.5%-14.9pp	-4.8%-4.0pp	13.3%-0.8pp	13.5%-4.2pp	8.4%+4.3pp	-0.8%+1.2pp	14.1%-6.3pp	17.8%+6.5pp

Note: Shareholder equity is negative (-$70.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Amneal Pharmaceuticals, Inc. AMRX	FY2025	$3.0B	$72.1M	2.4%	$7.1B	56/100
Prestige Consumer Healthcare Inc. PBH	FY2026	$1.1B	$190.3M	17.5%	$2.1B	61/100
Indivior Pharmaceuticals, Inc. INDV	FY2025	$1.2B	$210.0M	17.0%	$4.2B	44/100
PERRIGO COMPANY PLC PRGO	FY2025	$4.3B	-$1.4B	-33.5%	$2.0B	35/100
HUTCHMED (China) Limited HCM	FY2025	$548.5M	$456.9M	83.3%	$2.5B	42/100
Bausch Health Companies Inc BHC	FY2025	$10.3B	$157.0M	1.5%	$2.2B	51/100

Where Amneal Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

What is Amneal Pharmaceuticals, Inc.'s annual revenue?

Amneal Pharmaceuticals, Inc. (AMRX) reported $3.0B in total revenue for fiscal year 2025. This represents a 8.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Amneal Pharmaceuticals, Inc.'s revenue growing?

Amneal Pharmaceuticals, Inc. (AMRX) revenue grew by 8.0% year-over-year, from $2.8B to $3.0B in fiscal year 2025.

Is Amneal Pharmaceuticals, Inc. profitable?

Yes, Amneal Pharmaceuticals, Inc. (AMRX) reported a net income of $72.1M in fiscal year 2025, with a net profit margin of 2.4%.

What is Amneal Pharmaceuticals, Inc.'s EBITDA?

Amneal Pharmaceuticals, Inc. (AMRX) had EBITDA of $622.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Amneal Pharmaceuticals, Inc. have?

As of fiscal year 2025, Amneal Pharmaceuticals, Inc. (AMRX) had $282.0M in cash and equivalents against $2.6B in long-term debt.

What is Amneal Pharmaceuticals, Inc.'s gross margin?

Amneal Pharmaceuticals, Inc. (AMRX) had a gross margin of 36.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Amneal Pharmaceuticals, Inc.'s operating margin?

Amneal Pharmaceuticals, Inc. (AMRX) had an operating margin of 13.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Amneal Pharmaceuticals, Inc.'s net profit margin?

Amneal Pharmaceuticals, Inc. (AMRX) had a net profit margin of 2.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Amneal Pharmaceuticals, Inc.'s free cash flow?

Amneal Pharmaceuticals, Inc. (AMRX) generated $269.9M in free cash flow during fiscal year 2025. This represents a 11.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Amneal Pharmaceuticals, Inc.'s operating cash flow?

Amneal Pharmaceuticals, Inc. (AMRX) generated $340.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Amneal Pharmaceuticals, Inc.'s total assets?

Amneal Pharmaceuticals, Inc. (AMRX) had $3.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Amneal Pharmaceuticals, Inc.'s capital expenditures?

Amneal Pharmaceuticals, Inc. (AMRX) invested $70.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Amneal Pharmaceuticals, Inc. spend on research and development?

Amneal Pharmaceuticals, Inc. (AMRX) invested $186.2M in research and development during fiscal year 2025.

How many shares does Amneal Pharmaceuticals, Inc. have outstanding?

Amneal Pharmaceuticals, Inc. (AMRX) had 315M shares outstanding as of fiscal year 2025.

What is Amneal Pharmaceuticals, Inc.'s current ratio?

Amneal Pharmaceuticals, Inc. (AMRX) had a current ratio of 2.17 as of fiscal year 2025, which is generally considered healthy.

What is Amneal Pharmaceuticals, Inc.'s return on assets (ROA)?

Amneal Pharmaceuticals, Inc. (AMRX) had a return on assets of 2.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Amneal Pharmaceuticals, Inc.'s P/E ratio?

Amneal Pharmaceuticals, Inc. (AMRX) trades at 44.9x earnings, its market capitalization divided by net income of $157.4M net income, trailing 12 months to June 30, 2026. The market capitalization is $7.1B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Amneal Pharmaceuticals, Inc.'s price-to-sales ratio?

Amneal Pharmaceuticals, Inc. (AMRX) trades at 2.3x sales, its market capitalization divided by revenue of $3.1B revenue, trailing 12 months to June 30, 2026. The market capitalization is $7.1B as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is Amneal Pharmaceuticals, Inc.'s debt-to-equity ratio negative or not reported?

Amneal Pharmaceuticals, Inc. (AMRX) has negative shareholder equity of -$70.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Amneal Pharmaceuticals, Inc.'s Altman Z-Score?

Amneal Pharmaceuticals, Inc. (AMRX) has an Altman Z-Score of 2.44, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Amneal Pharmaceuticals, Inc.'s Piotroski F-Score?

Amneal Pharmaceuticals, Inc. (AMRX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Amneal Pharmaceuticals, Inc.'s earnings high quality?

Amneal Pharmaceuticals, Inc. (AMRX) has an earnings quality ratio of 4.72x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Amneal Pharmaceuticals, Inc. cover its interest payments?

Amneal Pharmaceuticals, Inc. (AMRX) has an interest coverage ratio of 1.63x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Amneal Pharmaceuticals, Inc.?

Amneal Pharmaceuticals, Inc. (AMRX) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.